treatment of patients
PAD therapy
treatment of CLI patients
PLX-PAD product
unmatched allogeneic PLX-PAD
clinical cell therapy
particular patients
action of PLX
prevalence of CLI
therapy response markers
clinical grade
clinical trials
mechanistic studies PACE
treatment of severe critical limb ischemia
off-the-shelf allogeneic placenta-derived stromal cell product
HLA-unmatched allogeneic placenta-derived stromal cells
limited treatment options
non-response
efficacy
revascularization
PACE partners
PACE consortium
traditional clinical trial endpoints of safety
Advanced Therapy Medicinal Products
D-cell manufacturing
high medical need
biomarker analyses
in-patient biomarker
medical care
multicenter phase IIb study
high risk of major amputation
year amputation-free survival
year mortality
safety of multiple intramuscular injections of HLA
parallel group phase
new therapeutic option
authorities
stratification
functional signature
world-leading experts
placebo
state-of-the-art characterizing molecular
ATMPs
novel
poor outcome
pilot project
knee
cardiovascular death
tolerability
Adaptive Pathways
disease
timely access
biomarkers
recognized expertise
depth
strong social impact
mechanisms
European Medicine Agency
incidence
improvements
population
female ratio
years